Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th

(marketscreener.com) Phio's INTASYL™ compounds demonstrated activity against multiple protein targets including PD-1, BRD4, CTLA-4, TIGIT and CTGF.INTASYL™ compounds demonstrated preclinical activity in both Direct-to-Tumor applications and Adoptive Cell Therapy applications .MARLBOROUGH, Mass., Nov. 10, 2022 /PRNewswire/ -- Phio Pharmaceuticals , a...https://www.marketscreener.com/quote/stock/PHIO-PHARMACEUTICALS-CORP-47281669/news/Phio-Pharmaceuticals-Announces-Study-Results-at-the-37th-Annual-Meeting-of-the-Society-for-Immunothe-42271423/?utm_medium=RSS&utm_content=20221110